In a data-driven world, pauses in government economic reporting do more than inconvenient economists, they create dangerous blind spots for investors, policymakers, and business leaders. When ...
The cost of GLP-1 medications to group health plans continues to increase rapidly as FDA approval expands and the percentage of participants and beneficiaries taking GLP-1 medications rises. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results